BioLineRx announced the enrollment of the first subject in a Phase I study of BL-1021, an orally available small molecule for treating neuropathic pain.
This clinical trial will be a first-in-human, single-site, double-blind, placebo controlled study to assess safety, tolerability, and pharmacokinetics of BL-1021 in healthy volunteers. The primary endpoints of the study are to examine the safety and tolerability of a single administration or multiple administrations of BL-1021., and Tthe secondary endpoints are the pharmacokinetics of single or multiple doses of BL-1021 in healthy subjects. The study will be carried out at the Hadassah Clinical Research Center (HCRC) and is expected to enroll up to 56 subjects.
“This is an important next step towards potentially making BL-1021 available as a treatment for neuropathic pain, which causes great suffering among millions of patients throughout the world, including diabetics and cancer patients,” states Kinneret Savitsky, MD, BioLine’s chief executive officer.
Release Date: July 05, 2011
Filed Under: Drug Discovery